pharmaphorum

MAY 6, 2022

Throughout my 30-year career, there have been many times it was obvious I stood out just because of my gender. I was often the only woman in the room, the meeting, or on the committee. Many colleagues had never worked with a woman leader before, let alone reported to a female boss. I’ve certainly faced barriers – sometimes literally. Exclusive behavior has many faces.

87

87

Pharma Times

MAY 6, 2022

Norfolk and Norwich University Hospitals Foundation Trust opens centre to increase survival rate among pregnant women managing other conditions

Hospitals 40

Hospitals 40

pharmaphorum

MAY 6, 2022

A digital therapeutic (DTx) developed to help people suffering from insomnia has been shown to improve sleep and mental health in people recovering from a stroke in a clinical trial. The use of the Sleepio app improved sleep quality in 48% of patients enrolled into the study, which was conducted with the University of Oxford. The study found Sleepio users experienced less depression and anxiety after eight weeks follow-up, according to the results, which were presented this week at the European

52

52

Pharma Times

MAY 6, 2022

WHO have stated that Veklury recommendation is being updated following compelling new evidence of hospital reductions

Hospitals 42

Hospitals 42

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 6, 2022

Biogen has licensed rights to a digital therapeutic (DTx) developed by MedRhythms which combines sensors, software, and music to help people with multiple sclerosis tackle mobility problems. The biopharma company – which is one of the top players in MS drug therapies – is paying $3 million upfront to claim rights to the DTx, known as MR-004, and is also on the hook for an additional $117.5 million in development and commercial milestones plus royalties on any eventual sales.

52

52

pharmaphorum

MAY 6, 2022

The PING Conference 2022 is back in person this year, with opportunities to network face-to-face with people from right across the life sciences ecosystem. We will be going back to the future…with a historic twist! Be informed and be inspired from leading speakers, be networked, be fed, and be entertained! We are delighted to bring you this year’s PING Conference 2022 with a high calibre of inspirational and informative speakers taking part in an entertaining in person format at The Old Palace

52

52

pharmaphorum

MAY 6, 2022

Forget the number of deaths worldwide from COVID-19 estimated by the various trackers of around six million. The true figures is much higher, at nearly 15 million, according to the World Health Organisation (WHO). The agency believes many countries have underestimated the number of deaths that can be directly or indirectly attributed to the coronavirus, in some cases by a massive margin.

52

52

pharmaphorum

MAY 6, 2022

Novartis has shut down production of its radioligand therapies – one of its key growth areas – at facilities in Europe and the US after discovering potential quality issues at the plants. The suspension affects sites at Ivrea in Italy and Millburn in New Jersey, and will affect both commercial and clinical trial supplies of its Lutathera for neuroendocrine tumours (NET) and recently-approved prostate cancer therapy Pluvicto.

FDA 52

FDA 52

pharmaphorum

MAY 6, 2022

Sanofi has completed the spin-out of its pharma ingredients business EuroAPI, with shares in the new company rising more than 3% on its starting price of €12 in early trading on the Euronext exchange this morning in a declining market. The separation makes EuroAPI the world’s single largest producer of small-molecule active pharmaceutical ingredients (APIs) – and the second-largest API producer overall after Israel’s Teva – with a market valuation of more than $1.2 billion.

64

64